…
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures for Gelteq Limited (ticker GELS) are limited and the company's core operations, revenue model and product offerings are not well documented in widely available filings or analyst coverage. Because detailed long-term growth drivers and strategy are not publicly clear, investors may find the stock's potential contingent on forthcoming disclosures that demonstrate a scalable business model and credible execution.
The primary investment risk is the substantial information gap—limited transparency creates execution, financing and valuation uncertainty that could lead to significant share-price volatility.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | -6.65M | -3.55M | -3.51M | -3.37M | -0.65M |
| Net income | -6.65M | -3.55M | -3.51M | -3.37M | -0.65M |
| Selling general administrative | 2.02M | 1.25M | 1.53M | 1.48M | 0.45M |
| Selling and marketing expenses | 0.20M | 0.02M | 0.17M | 0.07M | 0.01M |
| Gross profit | 0.17M | 0.00M | 0.03M | 0.05M | 0.00M |
| Reconciled depreciation | 1.22M | 1.21M | 1.23M | 1.22M | 0.06M |
| Ebit | -4.75M | -2.96M | -3.10M | -3.19M | -0.65M |
| Ebitda | -3.53M | -1.75M | -1.88M | -1.98M | -0.59M |
| Depreciation and amortization | 1.22M | 1.21M | 1.23M | 1.22M | 0.06M |
| Operating income | -5.50M | -2.95M | -3.10M | -3.19M | -0.65M |
| Other operating expenses | 5.66M | 2.95M | 3.18M | 3.34M | 0.65M |
| Interest expense | 1.89M | 0.59M | 0.40M | 0.17M | 0.00M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -1.95M | -0.60M | -0.40M | -0.18M | -0.00M |
| Total revenue | 0.17M | 0.00M | 0.08M | 0.15M | 0.00M |
| Total operating expenses | 5.66M | 2.95M | 3.13M | 3.25M | 0.65M |
| Cost of revenue | - | 0.00M | 0.05M | 0.09M | 0.00M |
| Total other income expense net | -1.15M | -0.60M | -0.40M | -0.18M | -0.00M |
| Net income from continuing ops | -6.65M | -3.55M | -3.51M | -3.37M | -0.65M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 21.48M | 20.76M | 22.49M | 23.41M | 24.22M |
| Intangible assets | 19.86M | 20.44M | 21.49M | 22.65M | 23.84M |
| Other current assets | 0.70M | 0.10M | 0.15M | 0.21M | - |
| Total liab | 5.67M | 5.65M | 3.84M | 2.55M | 0.40M |
| Total stockholder equity | 15.80M | 15.11M | 18.66M | 20.86M | 23.82M |
| Other current liab | 1.09M | 0.92M | 0.88M | 0.66M | 0.12M |
| Common stock | 33.95M | 26.61M | 26.61M | 25.30M | 24.93M |
| Capital stock | 33.95M | 26.61M | 26.61M | 25.30M | 24.93M |
| Retained earnings | -18.14M | -11.50M | -7.95M | -4.48M | -1.11M |
| Cash | 0.34M | 0.02M | 0.40M | 0.16M | 0.18M |
| Total current liabilities | 5.63M | 3.87M | 1.36M | 1.08M | 0.24M |
| Current deferred revenue | - | 0.13M | 0.09M | 0.12M | - |
| Net debt | 3.87M | 3.82M | 2.09M | 1.35M | -0.01M |
| Short term debt | 4.20M | 2.08M | 0.02M | 0.04M | 0.00M |
| Short long term debt | 4.20M | 2.08M | 0.01M | 0.01M | 0.00M |
| Short long term debt total | 4.22M | 3.84M | 2.49M | 1.51M | 0.17M |
| Total current assets | 1.51M | 0.30M | 0.99M | 0.72M | 0.37M |
| Net receivables | 0.46M | 0.18M | 0.35M | 0.25M | 0.19M |
| Long term debt | 0.01M | 1.76M | 2.47M | 1.46M | 0.17M |
| Inventory | - | 0.00M | 0.10M | 0.10M | 0.00M |
| Accounts payable | 0.18M | 0.39M | 0.29M | 0.22M | 0.09M |
| Accumulated other comprehensive income | - | - | - | 0.03M | - |
| Non currrent assets other | 0.09M | - | - | - | - |
| Non current assets total | 19.97M | 20.45M | 21.50M | 22.69M | 23.84M |
| Capital lease obligations | - | 0.00M | 0.01M | 0.05M | 0.00M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | -0.74M | -0.15M | -0.08M | 0.00M | 0.14M |
| Total cashflows from investing activities | -0.74M | -0.15M | -0.08M | - | 0.14M |
| Net borrowings | 0.48M | 0.84M | 0.72M | 1.49M | - |
| Total cash from financing activities | 6.45M | 0.84M | 2.03M | 1.49M | 0.00M |
| Net income | -6.65M | -3.55M | -3.51M | -3.37M | -0.65M |
| Change in cash | 0.32M | -0.37M | 0.24M | -0.02M | -0.14M |
| Begin period cash flow | 0.02M | 0.40M | 0.16M | 0.18M | 0.32M |
| End period cash flow | 0.34M | 0.02M | 0.40M | 0.16M | 0.18M |
| Total cash from operating activities | -5.52M | -1.07M | -1.77M | - | - |
| Issuance of capital stock | 7.91M | 0.00M | 1.43M | 0.00M | 0.00M |
| Other cashflows from investing activities | -0.73M | -0.15M | -0.04M | - | - |
| Other cashflows from financing activities | -1.94M | - | -0.12M | - | - |
| Capital expenditures | 0.64M | 0.15M | 0.08M | 0.00M | 0.00M |
| Other non cash items | -5.52M | 2.48M | 1.74M | - | - |
| Free cash flow | -6.16M | -1.22M | -1.85M | -1.51M | -0.28M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| GELS Gelteq Limited Ordinary Shares |
-0.08 21.54% |
0.28 | - | - | 13.98 | 0.71 | 92.13 |
| MKKGY Merck KGaA ADR |
0.30 0.92% |
33.03 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
169.65 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.11 0.51% |
21.70 | - | 10.96 | 0.01 | 1.20 | 2.94 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.15 | - | 10.66 | 0.01 | 1.16 | 2.94 |
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Nathan Jacob Givoni | Co-Founder, CEO & Executive Director | 1984 |
| Mr. Simon Hayden Szewach | Co-Founder & Non-Executive Chairman | 1980 |
| Ms. Thuy-Linh Gigler | Chief Financial Officer | 1980 |
| Dr. Paul M. Wynne Ph.D. | Chief Scientific Officer | 1963 |
| Bradley Glenn Karp | Head of Sales & Marketing | NA |
| Mr. Adam Bendell | President of U.S. Operations | NA |
| Mr. Matthew Jones | Head of Sports Performance | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.